Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Upd...
March 20 2020 - 7:30AM
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on
discovering, developing and commercializing transformative
therapies to treat rare and underserved ophthalmic diseases, today
announced that it will release its 2019 financial results and
provide a business update before the open of the U.S. financial
markets on Friday, March 27, 2020. The company will host a
conference call at 8:30 a.m. ET on the same day to discuss the
results and provide a business update.
The call can be accessed by dialing (844) 873-7330 (U.S.) or
(602) 563-8473 (international) and providing the conference ID
5373849. To access a live audio webcast of the call on the
“Investors” section of the Ocugen website, please click here.
A replay of the webcast will be archived on Ocugen’s website for
approximately 45 days following the call.
About Ocugen, Inc. Ocugen, Inc. is a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing transformative therapies to treat
the whole eye. Our Phase 3 small molecule drug candidate for ocular
Graft Versus Host Disease (oGVHD), if approved, will be the first
and only treatment for this orphan disease. Our breakthrough
modifier gene therapy platform has the potential to treat multiple
retinal diseases with one drug – “one to many”. And our novel
biologic product candidate aims to offer better therapy to patients
with underserved diseases such as wet age-related macular
degeneration, diabetic macular edema and diabetic retinopathy. For
more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from the Company’s current expectations. These and other
risks and uncertainties are more fully described in our periodic
filings with the Securities and Exchange Commission (the “SEC”),
including the risk factors described in the section entitled “Risk
Factors” in the Company’s Quarterly Report on Form 10-Q filed with
the SEC on November 12, 2019. Any forward-looking statements that
the Company makes in this press release speak only as of the date
of this press release. Except as required by law, the Company
assumes no obligation to update forward-looking
statements contained in this press release whether as a result of
new information, future events or otherwise, after the date of this
press release.
Corporate Contact:
Ocugen, Inc.
Kelly Beck
kelly.beck@ocugen.com
+1 484-328-4698
Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024